Ra Pharmaceuticals,Inc. (NASDAQ:RARX) Files An 8-K Submission of Matters to a Vote of Security Holders

Item5.07. Submission of Matters to a Vote of Security
Holders.

(a) On June20, 2017, Ra Pharmaceuticals,Inc. (the
Company) held its 2017 Annual Meeting of
Stockholders (the Annual Meeting) at
10:00a.m.Eastern Time at the offices of Goodwin ProcterLLP, 100
Northern Avenue, Boston, MA 02210. Proxies for the Annual Meeting
were solicited to Regulation 14A of the Securities Exchange Act
of 1934, as amended.

(b) The following matters, which are described in detail in the
Companys definitive proxy statement filed with the U.S.
Securities and Exchange Commission on April28, 2017, were voted
upon at the Annual Meeting with the number of votes cast in
respect thereof as set forth below:

1. Election of each of Douglas A. Treco, Ph.D. and Edward T.
Mathers to serve as a ClassI Director of the Company for a
three-year term, expiring at the 2020 annual meeting of
stockholders and until their respective successors are duly
elected and qualified, subject to their earlier resignation or
removal.

Douglas A. Treco, Ph.D.

Votes:

Edward T. Mathers

Votes:

Accordingly, each of the foregoing nominees was elected to serve
as a ClassI Director of the Company.

2. Ratification of the appointment of Deloitte ToucheLLP as the
Companys independent registered public accounting firm for the
fiscal year ending December31, 2017.

Votes:

Accordingly, the appointment of the Companys independent
registered public accounting firm was ratified.

About Ra Pharmaceuticals, Inc. (NASDAQ:RARX)

Ra Pharmaceuticals, Inc. is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutics for diseases of complement dysregulation and a range of orphan indications. It utilizes small molecules and peptide approaches to address pathological targets in the complement cascade. It has leveraged the Extreme Diversity peptide chemistry platform to develop a portfolio of products that selectively inhibit the complement system and other immune targets. Its main program, RA101495, is a macrocyclic peptide inhibitor of complement component 5 (C5), which is in Phase I stage of development for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). RA101495 binds a site on the C5 protein to inhibit cleavage into C5a and C5b, thereby preventing red blood cell lysis by inhibiting the production and assembly of the membrane attack complex (MAC). RA101495 is being developed as an alternative to eculizumab therapy for patients with PNH.

Ra Pharmaceuticals, Inc. (NASDAQ:RARX) Recent Trading Information

Ra Pharmaceuticals, Inc. (NASDAQ:RARX) closed its last trading session down -0.83 at 22.18 with 628,161 shares trading hands.